|
 
- 现金
- 1145 元
- 精华
- 0
- 帖子
- 847
- 注册时间
- 2011-2-14
- 最后登录
- 2024-7-13
|
本帖最后由 风雨不动 于 2012-4-14 15:41 编辑
http://www.dynavax.com/hepatitis_bt.html
The study evaluated three doses of the candidate therapeutic vaccine escalation in 14 patients with chronic hepatitis B infection, including six patients that were HBeAg negative and eight patients who were HBeAg positive, and found:
- The therapeutic regimen was safe and generally well tolerated at all dose levels;
- Most common systemic reactions were fatigue and malaise. No SAEs were recorded;
- DV601 was found to elicit immune responses at all dose levels, and anti-HBe antibodies were elicited in two of eight (2/8) patients;
- Anti-HBs antibodies were elicited in four of 14 (4/14) patients;
- Amongst the eight HBeAg positive patients, two had HBeAg clearance, and one of those individuals also had HBsAg clearance;
- Three patients are still in the follow-up observation period.
简单翻译一下:
临床研究评估了针对14名患有慢性乙肝的病人(这14人种有6例属于HbeAg阴性患者,8例HbeAg阳性患者)注射该治疗性疫苗3次后的疗效.
1、这种疗法安全并且受试者能够忍受各种剂量带来的不良反应（就是这14人都能忍受）。
2、大多数受试者的全身反应是极度疲劳和不适。没有SAEs记录（不知道这SAEs代表什么意思）。
3、DC601(该疫苗的名称）在任何剂量下都能够激发免疫系统的应答，8名大三阳患者中有2人产生抗HBe抗体。
4、14名患者中4人出现表面抗体。
5、8个大三阳患者中有2人HBeag被清除，并且其中一人的表面抗原消失。
6、有3位患者继续观察治疗。
本人参加工作后一直没有碰过英语，翻的不好请见谅。
(6.合.彩)足球.篮球-...各类投注-开户下注
第一投注-现金网:招代理-年薪10万以上:585895.com |
|
发表于 2011-3-26 16:21
